LifeMD (NASDAQ:LFMD) Given “Overweight” Rating at Cantor Fitzgerald

LifeMD (NASDAQ:LFMD)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 188.46% from the stock’s current price.

A number of other research firms have also weighed in on LFMD. B. Riley started coverage on shares of LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 price target for the company. KeyCorp dropped their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.00.

LifeMD Stock Performance

Shares of LFMD stock traded down $0.08 during trading hours on Friday, reaching $5.20. The company had a trading volume of 216,588 shares, compared to its average volume of 771,693. The firm has a market cap of $217.14 million, a PE ratio of -7.03 and a beta of 1.19. The business has a fifty day moving average price of $5.74 and a 200-day moving average price of $7.85. LifeMD has a one year low of $4.05 and a one year high of $12.88. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.83 and a current ratio of 0.87.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to analyst estimates of $48.47 million. During the same quarter last year, the firm earned ($0.23) earnings per share. Sell-side analysts predict that LifeMD will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quest Partners LLC acquired a new position in shares of LifeMD during the second quarter valued at about $31,000. Los Angeles Capital Management LLC acquired a new position in LifeMD during the 2nd quarter valued at approximately $88,000. EntryPoint Capital LLC purchased a new position in shares of LifeMD in the first quarter worth $89,000. The Manufacturers Life Insurance Company acquired a new stake in shares of LifeMD during the second quarter worth $93,000. Finally, XTX Topco Ltd purchased a new stake in shares of LifeMD during the second quarter valued at $94,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.